US equities
|
NVDA
$236.91
▲+1.27%
SPCX
$166.87
▲+4.97%
MU
$1,066.70
▼-0.76%
TSLA
$377.02
▲+1.74%
MSFT
$526.96
▲+1.82%
INTC
$117.37
▼-1.65%
SNDK
$1,726.10
▲+0.35%
META
$743.69
▲+2.14%
NVDA
$236.91
▲+1.27%
SPCX
$166.87
▲+4.97%
MU
$1,066.70
▼-0.76%
TSLA
$377.02
▲+1.74%
MSFT
$526.96
▲+1.82%
INTC
$117.37
▼-1.65%
SNDK
$1,726.10
▲+0.35%
META
$743.69
▲+2.14%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Avantis International Equity ETF
(NY:
AVDE
)
90.06
-0.27 (-0.30%)
Delayed Quote
Updated: 10:24 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Avantis International Equity ETF
< Previous
1
2
Next >
Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock
↗
March 10, 2026
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.
Via
Stocktwits
Topics
Intellectual Property
Lawsuit
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy
↗
March 09, 2026
Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.
Via
Stocktwits
Topics
Intellectual Property
Lawsuit
Mason Buys Over $3 Million of COWG
↗
February 25, 2026
This ETF targets U.S. large-cap companies with strong free cash flow, using a systematic approach to identify growth leaders.
Via
The Motley Fool
Topics
ETFs
Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant
↗
October 07, 2025
Via
Stocktwits
Novo Nordisk To Reportedly Cut Yearly Bonus For Denmark Employees: Retail Expects Stock To Hit $80 By Year-End
↗
August 22, 2025
Via
Stocktwits
Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report
↗
February 24, 2026
According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027.
Via
Stocktwits
Topics
Artificial Intelligence
NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China
↗
February 24, 2026
Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.
Via
Stocktwits
Why Is NVO Stock Falling Pre-Market Today?
↗
February 23, 2026
The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.
Via
Stocktwits
Topics
Government
Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly
↗
February 11, 2026
Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.
Via
Stocktwits
Topics
Intellectual Property
FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains
↗
February 09, 2026
According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy.
Via
Stocktwits
Topics
Lawsuit
Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks
↗
February 09, 2026
Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.
Via
Stocktwits
Topics
Intellectual Property
Lawsuit
Budweiser Maker’s Stock Gets Crushed After Q2 Gloom — Retail Traders Feel 'Drop Is A Bit Unjustified'
↗
August 01, 2025
U.S.-listed shares of the world's largest brewer marked their worst day in over five years after the company missed revenue and volume estimates.
Via
Stocktwits
Topics
Government
US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies
↗
June 18, 2025
The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported.
Via
Stocktwits
Topics
Lawsuit
Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking
↗
June 12, 2025
The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.
Via
Stocktwits
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels
↗
June 11, 2025
Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.
Via
Stocktwits
Topics
Artificial Intelligence
Economy
Toyota Industries Likely To Accept $42B Takeover Bid From Toyota Motor And Group Companies, Says Report: Retail’s Undecided
↗
June 02, 2025
The consortium is expected to take Toyota Industries private after it accepts the tender offer, with the takeover bid estimated at 6 trillion yen, or approximately $42 billion.
Via
Stocktwits
Topics
Supply Chain
Toyota Records Fourth Straight Month Of Sales Jump In April: But Retail’s Not Yet Convinced
↗
May 29, 2025
The company reported a 25% jump in sales of electrified vehicles last month, owing to a 24% increase in sales of hybrid electric vehicles in particular, which touched 378,976 units.
Via
Stocktwits
Topics
Government
World Trade
Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish
↗
May 22, 2025
The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy.
Via
Stocktwits
Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes
↗
May 16, 2025
The company said it would announce the next CEO in “due course,” but did not provide a more definite timeline.
Via
Stocktwits
Budweiser Maker AB InBev Plans $300M Investment To Expand US Production: Retail Turns Bullish
↗
May 13, 2025
As part of the plan, the company will also open a new plant in Ohio.
Via
Stocktwits
Topics
Government
Toyota Expects 21% Profit Decline In FY26: Retail’s In Wait-And-Watch Mode
↗
May 08, 2025
The company said that the new forecast includes a negative impact of 180 billion yen from U.S. tariffs for April and May, and an estimated 745 billion yen impact from the effects of the foreign...
Via
Stocktwits
Topics
World Trade
Novo Nordisk Stock Rises Pre-Market On Q1 Beat Despite Lowering Outlook – Retail’s Elated
↗
May 07, 2025
Sales of Novo Nordisk’s flagship weight loss drug Wegovy surged 85% in the first quarter of the fiscal year 2025, while its diabetes treatment Ozempic posted an 18% increase.
Via
Stocktwits
Topics
Earnings
Law Enforcement
Why Is UBS Stock Trading Lower On Wednesday?
↗
April 30, 2025
UBS Group AG shares are down 1% Y/Y, with revenues of $12.56 billion missing consensus. CEO remains focused on clients and financial targets.
Via
Benzinga
Novo Nordisk’s Weight-Loss Drug Wegovy Launched In Thailand, Marks Entry Into Southeast Asia
↗
April 28, 2025
Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023.
Via
Stocktwits
Novo Nordisk Wins Another Legal Battle Against Compounding Of Wegovy, Ozempic: Retail’s Bullish
↗
April 25, 2025
Steve Benz, legal and US general counsel of Novo Nordisk, said the company is “pleased” that the court rejected the compounders' attempts to “undermine” the FDA's decision that the shortages of Wegovy...
Via
Stocktwits
Topics
Lawsuit
Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish
↗
April 15, 2025
Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize...
Via
Stocktwits
Topics
Stocks
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved
↗
April 14, 2025
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517.
Via
Stocktwits
Topics
Economy
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish
↗
April 02, 2025
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its...
Via
Stocktwits
Novo Nordisk Stock Slips After BofA, Morgan Stanley Slash Price Targets – But Retail Goes Contrarian
↗
March 28, 2025
Bank of America analysts said Novo Nordisk might miss first-quarter estimates. According to TheFly, they expect the company to lower its full-year sales guidance from 16%-24% at constant exchange rates...
Via
Stocktwits
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves
↗
March 24, 2025
Novo Nordisk will obtain exclusive worldwide rights to develop, manufacture, and commercialize the drug UBT251, while United Biotechnology will, however, retain the rights to the drug in mainland...
Via
Stocktwits
< Previous
1
2
Next >
